AmpliChip CYP450 prototype microarray assay, along with allele-specific-PCR and PCR restriction fragment length polymorphism methods. No significant difference was noted between controls and psychiatric patients in any CYP2D6 allele frequencies. Three subjects were genotyped as poor metabolizers (1.4%; 0.0-2.9%, 95% confidence intervals (CI)), and 10 were classified as ultrarapid metabolizers (4.5%; 1.8-7.2%, 95% CI). A new CYP2D6 allele (*58) and two new duplicated CYP2D6 alleles (*17xn and *2Lxn) not previously reported were also identified. The frequency of the CYP2D6 overexpression in African-Americans may represent a greater therapeutic challenge than its deficiency based on these results. The most common alleles found in African-Americans including CYP2D6*1, *17 and *41 need to be investigated more closely for race-specific allelic variations and the mechanism responsible for differences in allele function more closely examined. The diversity of CYP2D6 alleles suggests that nucleotide arrays or similar methods are needed to efficiently test for the most prominent/ relevant CYP2D6 alleles in humans.
Introduction
Today, African-Americans represent 36 million people in the US 1 and more globally, the population on the African continent now exceeds 884 million people, the vast majority of whom are native Africans. 2 African-Americans (originally transported to the US from the western parts of Africa) make up 12% of the US population, but account for a disproportionate frequency of individuals with certain chronic diseases, such as cardiovascular disease, hypertension, certain cancers and renal failure. [3] [4] [5] [6] [7] Although African-Americans are not overrepresented among the psychiatric patient population, psychiatric patients are one group (and African-Americans an important subgroup within it) who are likely to be prescribed drugs that depend on the CYP2D6 enzyme for their elimination. African-Americans constitute 16% of all patients admitted to psychiatric hospitals in Kentucky.
The management of medical conditions in black population in general and African-Americans in particular is affected by variation in the expression of metabolic enzymes involved in drug elimination. 8, 9 Unfortunately, there remains a limited body of information on the frequency of the growing numbers of alleles associated with the CYP2D6 gene in the black population. One issue is whether or not CYP2D6 alleles reported in Caucasians are appropriate alleles to assess in African-Americans for drug disposition [10] [11] [12] [13] [14] [15] [16] and if not, what specific CYP2D6 alleles should be evaluated clinically among African-Americans. Racial divergence between black subjects and Caucasians is estimated to have occurred over 50 000 years ago, and it now appears that these different races may express a somewhat different constellation of CYP2D6 alleles. 14, 17, 18 The CYP2D6 alleles with the greatest potential therapeutic impact are those that produce the most extreme effects on enzyme activity and that appear in the population with some degree of regularity. Alleles that result in no enzyme expression (poor metabolism phenotype), very low enzyme activity (intermediate metabolism phenotype) or that are typically associated with overexpression of a metabolic enzyme (ultrarapid metabolism phenotype) will likely deserve the most attention in clinical settings. The CYP2D6 enzyme has attracted substantial interest because of its role in the metabolism of many therapeutically important drugs, particularly those used to treat cardiovascular disease and psychiatric disorders. 8, [19] [20] [21] The purpose of this research was to characterize the CYP2D6 alleles and the frequency of each allele in African-Americans. This information was then used to define the criteria for CYP2D6 allele detection in AfricanAmerican subjects and what future research on CYP2D6 allele characterization remains to be carried out in this racial group.
Results
Frequency of CYP2D6 alleles A summary of each CYP2D6 allele tested and its frequency is provided in Table 1 for a healthy group, a psychiatric group and the combined group of African-American subjects. Little difference was noted in the frequency of CYP2D6 alleles between the healthy control group and psychiatric patients although the small group sizes prevent small differences that may exist from being detected as significant. Most CYP2D6 alleles were within 1-2% of each other between the two groups. The sum of all CYP2D6 null alleles (*3, *4, *5, *6, *7, *8, *11, *15 and *4xn) tested (66/444) gave an observed allelic frequency of 14.9% and a predicted phenotype frequency of 2.2% for the CYP2D6 deficiency or poor metabolizer phenotype. This predicted frequency was not significantly different from the 1.4% (0.0-2.9%; 95% confidence intervals (CI)) observed for the CYP2D6 'null' genotype. The CYP2D6*17 allele was detected with a frequency of 14.9% (11.6-18.2%; 95% CI). The composite CYP2D6 *41 allele occurred with a frequency of 14.4% (64/ 444) (11.1-17.6%; 95% CI). Together, the *1, *17 and *41 alleles accounted for an estimated 64.6% of the total alleles in African-Americans. The *29, *4 and *5 alleles occurred with roughly similar frequencies of 5-7%. The *2 allele in African-Americans was slightly less common, accounting for only 4.5% of the total CYP2D6 alleles in African-Americans.
The CYP2D6*29, *41, *17 and *2 alleles and alleles related to them (*30, *40, *35, *58, *42, *45 and *46) all contain the same constellation of exon variations (1661C, 2850T and 4180C). If additional single nucleotide polymorphism (SNP) tests are not performed, these alleles are grouped together The *40, *58, *43, *10xn, *17xn, *41xn and *2Lxn allele designations were confirmed by sequencing the relevant regions of the CYP2D6 gene. and account for the over-estimation of the true *2 allele frequency (see Table 2 ). [10] [11] [12] [13] [14] [15] [16] 22 Frequency of deficient and intermediate metabolism Comparing observed and predicted frequencies for CYP2D6 allele combinations according to Hardy-Weinberg equilibrium suggests that healthy controls, psychiatric patients and the combined groups conform to the expected ratios (Table 3 ). An estimated 2.2% of African-Americans are expected to express the 'null' CYP2D6 phenotype based on currently tested/evaluated null CYP2D6 alleles.
Combining the frequency of the tested alleles that are thought to lower CYP2D6 activity (*9, *10, *17, *29, *40 and *43 alleles) in psychiatric patients suggests that up to 26.6% of CYP2D6 alleles in African-Americans could have moderately to significantly reduced CYP2D6 activity. Coupling known null alleles (*3, *4, *5, *6 or *4xn) with a reduced activity allele (*9, *10, *17, *29, *40, *43) would be expected to result in an individual who exhibits low or intermediate CYP2D6 activity in about 3.9% of African-Americans (0.146 Â 0.266). 23 Two reduced activity alleles (i.e., any combination of alleles with reduced CYP2D6 activity -*9, *10, *17, *29, *40, *43) may also produce low or intermediate CYP2D6 activity. A combination of two alleles with purported reduced activity (*9, *10, *17, *29, *40, *43) should occur with a frequency of around 7% in African-Americans, suggesting that up to 10.9% (3.9 þ 7%) of African-Americans may exhibit low to moderate CYP2D6 function based on currently known CYP2D6 alleles of anticipated reduced function. 0.020 The frequency of the inactive mutant allele (m) was determined by combining the frequency for CYP2D6 alleles *3, *4, *5, *6 and *4xn in each group. All other identified alleles were treated like wild-type (wt) alleles. Differences between the observed and expected frequencies were not significant by a w 2 goodness-of-fit test (P40.05).
Multiple copy and new CYP2D6 alleles A surprising observation was the identification of five different multiple copy alleles in the African-American population (*4Dxn, *10Bxn, *17xn, *41xn and *2Lxn) some of which are not typically reported in this racial group. Two of these duplicated alleles (*17xn and *2Lxn) have never been reported before in any population. The *41xn and *2Lxn alleles were identified by testing a 9.5 kb amplicon for the presence of the À1584C/G polymorphism in the promoter region of the trailing CYP2D6 gene. These alleles were found to contain À1584C, whereas all other tests indicated the presence of a *2xn like allele. Two of these duplicated *41xn alleles contained a gene conversion element in intron 1 (*41xn) and one did not contain the gene conversion element in intron 1 (*2Lxn). Only one *41xn allele has been sequenced by us through the entire intron 6 region to confirm that it contained a *41 allele with a 2988G nucleotide. According to recent nomenclature changes, this would now be classified as a *2Axn allele. The *10Bxn was identified when the genotype from 9.5 kb amplicon was discordant with the genotype determined by allele-specific-PCR (AS-PCR) and the AmpliChip CYP450 assay. The 9.5 kb amplicon indicated a mutation in exon 9 (4180C) and exon 1 (100T), consistent with a multiple copy *4 allele. However, the test for the 1846A point mutation at the intron 3-exon 4 border failed to identify a *4 allele either by standard PCR tests or the AmpliChip CYP450 assay. The AmpliChip CYP450 data indicated a *1/*10B genotype also containing the 1039T variation. The only explanation was the presence of a *10Bxn allele. A similar situation led to the identification of the *17xn allele, when genetic tests indicated a *1/*17 genotype and the 9.5 kb amplicon indicated the multiple copy CYP2D6*2-like allele. All five multiple copy alleles were subsequently amplified and sequenced from the leading exon #9 CYP2D6 gene through exon #6 of the trailing CYP2D6 gene to confirm their respective allele assignment. A *40 variant allele (recently given the allele designation *58; GenBank accession #DQ282162) was identified when the allele-specific test for the *40 allele indicated an insertion less than 18 bp. Sequencing of this allele from intron 1 through exon 6 confirmed the presence of a 9 bp insertion in exon #4 rather than the 18 bp insertion, which is found in *40 alleles. It also contained the 1023T, 1661C and 2850T variants, in addition to a gene conversion element in intron 1.
Discussion
Aim #1 -frequency of CYP2D6 alleles in African-Americans There was no significant difference in CYP2D6 alleles between psychiatric patients and healthy control subjects (Table 1 ) and no indication of stratification in either group (Table 3) . Based on this observation, the normal controls and psychiatric patient groups were combined. Previously, there has been only one fairly thorough study of the numerous known CYP2D6 alleles in African-Americans. 14 In this study, a new CYP2D6 allele (*58 allele) was identified as a result of the current testing efforts (GenBank accession #DQ282162). Whereas the poor metabolism phenotype in African-Americans is estimated to be only 2% based on currently confirmed null CYP2D6 alleles evaluated, 19 in vivo CYP2D6 activity measurements suggest that the frequency for poor metabolism in African-Americans may be closer to 7%.
14 Whether this difference is due to functional alleles with low efficiency for metabolism of dextromethorphan (*17, *29, *41 and/or related alleles) or the presence of unidentified null CYP2D6 alleles related to these or other alleles is unclear, but deserves closer investigation.
The CYP2D6*17 allele has been reported with a frequency ranging from 14.6 to 26% among African-Americans (Table  2 ). These differences could reflect sampling variation with the true frequency for the *17 allele closer to a value between 14.6 and 26%. In this study, the frequency of the *17 allele was 14-15% based on the AmpliChip CYP450 prototype microarray test, which identified five separate point mutations (À1584C, 1023T, 1661C, 2850T, 4180C) plus the gene conversion element in intron #1 in a parallel fashion. The standard PCR tests queried these same samples separately for a À1584C, 1023T and gene conversion element. However, the key variation that distinguishes *17-related alleles from all other types of unrelated CYP2D6 alleles is the 1023T. The use of extensive tests in this study was carried out primarily to try and identify new allele variations rather than just confirm the presence of a *17 allele. Recently, the 1661C variation has been listed as part of the constellation of nucleotide variations present in the *17 allele. 24, 25 This nucleotide variation has been found in almost every CYP2D6*17 allele and related alleles (*17xn, *40 and *58) identified thus far in African-Americans, but not in all *17 alleles, suggesting the presence of additional variants in the *17 allele group. 17 The *40 and *58 allele accounted for only a small fraction of the *17 alleles, representing just 1-2% of this total.
The composite CYP2D6*41 allele was very frequent in African-Americans (14-15%) based on tests that identified the À1584C, gene conversion in intron 1, 1661C, 2850T and 4180C point mutations. The composite *41 allele has recently been re-defined as *41 if it contains the 2988G4A, and as *2A if the 2988G is present. This study did not attempt to re-group the *41 alleles into 2988G and 2988A variations or even separate the *2L, *45 and *46 alleles from the *41 composite allele. Instead, these have all been grouped together as a single composite *41 allele. However, the majority (75%) of *41 alleles identified in this manner carried the gene conversion element in intron #1, but an estimated 25% of *41 alleles (3.6% of total alleles) did not have this gene conversion element. Variants without a gene conversion element were attributed in part to a combination of *2L; *45 and *46 alleles. Based on two additional SNPs in the coding region of the CYP2D6 gene, a 1716 G4A in exon 3 changing Glu(155)Lys, and a silent 2575 C4A variation in exon 5, some of these alleles are known to be *45 and *46 alleles. 18 Unfortunately, it was not possible to test for every one these alleles in each sample, so it was decided to lump them together into the *41 allele composite group by default. However, the frequency of the *45/*46 allele clade indicates that they represent a significant portion of the CYP2D6 alleles among African-Americans and deserve closer investigation in future studies.
Together the *1, *17 and *41 composite allele groups represented the three most common groups in AfricanAmericans, and accounted for over 64% of the total CYP2D6 alleles in this population. Based on known clustering of allele variants related to the most common alleles found in Caucasians (*1, *2, *4), 17 there is a high probability that new alleles in African-Americans will likely share a strong homology with the *1, *17 and *41 alleles found in black subjects. It is interesting that a number of alleles that are related to the *1 allele in Caucasians (*7, *8, *15, *18, *25, *26) have not been observed in African-Americans. This is most likely owing to the rarity of these CYP2D6 alleles even in Caucasians. 17 It is of interest that 4.5% of African-Americans had a predicted phenotype of ultra-rapid metabolism based on genotypes typically associated with high CYP2D6 activity (*2Axn/*1, *2Axn/*2A). A high level of CYP2D6 activity may be of greater therapeutic concern for African-Americans than the absence of CYP2D6 expression, as this phenotype occurred with a frequency three times that of the predicted CYP2D6 poor metabolism phenotype in this racial group.
Some of the CYP2D6 duplicated alleles found in AfricanAmericans include *2A, *4D, *10, *17, *41 and *2L. This suggests that CYP2D6 gene duplication represents a fairly common evolutionary event in humans, occurring on at least 11 separate occasions (*1xn, *2Axn, *2Dxn, *4Axn, *4Dxn, *10Bxn, *17xn, *35xn, *36xn, *41xn, *2Lxn) after the CYP2D6 gene arose. Recent sequencing evidence even suggests that the *1xn duplication in African-Americans arose from a slightly different allele than the one from which the *1Axn in Caucasians is derived GenBank accession #'s DQ282144; DQ282145). Thus, even duplicated alleles that appear the same may have arisen in separate races at separate times by separate duplication events. As the duplication of this CYP2D6 gene is so common, additional CYP2D6 gene duplications probably exist that have yet to be discovered. The recent report of the *36xn allele in Asians, the *41xn and a probable *9xn serve as good examples to illustrate this point. [26] [27] [28] An interesting observation is that the same CYP2D6 allele seems to be almost always duplicated. One exception to this general rule is the recently reported CYP2D6 tandem allele *36-*10B (GenBank accession #DQ211353). The more usual duplication of the same CYP2D6 allele is difficult to explain based on a proposed unequal crossover event between two separate chromosomes. 29 One would anticipate that such unequal crossover events would produce mostly duplicated (tandem) CYP2D6 alleles that reflect the most abundant alleles in the population. The AmpliChip CYP450 microarray data and PCR tests indicate that most of the CYP2D6 duplicated alleles studied to date are identical alleles, even though the CYP2D6 allele being duplicated may not be that prevalent in the population (e.g., *2Dxn, *2Lxn). Given the large number of duplicated CYP2D6 alleles identified thus far, there must be some additional factor(s)/restrictions that explain why one allele is nearly always duplicated, rather than a mix of two different CYP2D6 alleles.
The presence of the *1-related alleles (*3 -0.5%, *6 -0.2% and *9 -0.5%) in African-Americans (Table 2 ) occurs with a frequency of about 20-25% of the corresponding frequencies for these alleles in Caucasians (*3 -2%; *6 -1%; *9 -3%). 30 Similarly, lower frequencies for the identical *2A allele (with a À1584G) have been observed in African-Americans (4.5%) versus Caucasians (18%)) and for the related *35 allele (0.7% in black subjects and 5% in Caucasians; Table 2 ). Within the experimental error, these allele frequencies are in basic agreement with the predicted 20-25% admixture between the African-American and Caucasian races. 31 Aim #3 -questions and future research required on CYP2D6 alleles in black population The clinical relevance of not being able to distinguish a *41 allele from the *2A allele in black subjects remains uncertain. It is unclear if the CYP2D6*2A and CYP2D6*41 alleles really exhibit significant differences in CYP2D6 activity or if the differences that have been observed reflect additional parameters that are poorly understood at present. 26 One of the key problems thus far in the study and interpretation of CYP2D6 genotypes is the poor appreciation of the mechanistic reasons for differences between alleles. If an allele results in a general depression of CYP2D6 enzyme expression, one anticipates that this would lead to a global decrease in the metabolism of all substrates whenever this allele is expressed. 32 However, if an allele alters the structure of the CYP2D6 enzyme without changing the level of its expression, a real possibility exists that differences in metabolism by the allele will be substrate-dependent. It is often unclear if a CYP2D6 allele results in a global or selective reduction in metabolism because the effect various alleles have on CYP2D6 expression is not typically examined. This may be one reason why variations in probe substrate metabolic ratios differ so markedly in African-Americans. 33 The concept of allele substrate-dependent versus allele global depression in CYP2D6 function is easiest to visualize from the CYP2D6*17 allele perspective. The CYP2D6*17 allele has generally been characterized as an allele with diminished CYP2D6 activity, 24, 25, [34] [35] [36] but there is some evidence that this classification is wrong. 35, 33 The psychiatric patients evaluated in this study came from a larger group of patients prescribed risperidone in which the risperidone and 9-OH risperidone levels were determined. 37 The risperidone/9-OH ratio in patient plasma is dependent on CYP2D6 activity as 9-OH risperidone is formed by CYP2D6 metabolism of risperidone. 19, [38] [39] [40] It was notable that this ratio was not increased by the expression of the CYP2D6*17 allele in African-Americans (as would be expected for a CYP2D6 allele resulting in reduced activity), but rather decreased (Figure 1 ). This suggests the CYP2D6*17 allele may facilitate risperidone metabolism rather than diminish its metabolism. A likely reason for this unexpected result is that the *17 allele results in a structural change in the CYP2D6 enzyme, not a global depression in its expression. Consequently, substrate turnover by this allele depends on the substrate evaluated. A critical objective of CYP2D6 allele evaluation should be to characterize the molecular basis for altered CYP2D6 allele function, rather than base conclusions about diminished allele activity solely on the results of how a single substrate, probe or related substrates are metabolized by an allele. A much better understanding of the relevance and mechanism for altered CYP2D6 allele function in African-Americans is warranted.
The difference in the prevalence of *2A and *41 alleles is important to understanding racial differences in CYP2D6 allele expression. African-Americans are somewhat different from Caucasians in their CYP2D6 allele make-up. Past efforts that have not tested for the presence of the *41 allele have resulted in the *2 allele appearing far more prevalent in African-Americans than it actually is ( Table 2 ). Rare *2A-related alleles identified in Caucasians (*8/*14, *11, *12, *21, *30) were not detected in African-Americans, and would not be expected to contribute significantly to its composite allele frequency. More research should be carried out to assess the true frequency of the *2A and related alleles in native African populations, to identify allele variations in the *41, *45 and *46 allele groups in black population and the mechanism(s) responsible for differences in CYP2D6 enzyme function.
Aim #2 -criteria for CYP2D6 allele detection in African-Americans and other racial groups The true percentage of null and low-activity CYP2D6 alleles in African-Americans is unknown, but this raises a critical question -how many CYP2D6 alleles should be evaluated in clinical settings? The CYP2D6*7, *11, *12, *13, *15, *16, *18, *19, *20, *22-*28, *30, *31-34, *38, *39, *44, *50, *51, *52, *54, *55 appear to be fairly infrequent alleles (p0.2%) in all racial groups in which they have been characterized. 22 Should each CYP2D6 allele ever identified be evaluated? As the number of CYP2D6 alleles increase with more detailed evaluation of various racial groups and populations, it will likely become unnecessary to test for every allele, especially those that are infrequent or for which there is minimal impact on enzyme activity. Rather, a subset of all known CYP2D6 alleles should be defined based on their prevalence in various racial groups. A cutoff of between 0.2% (1 in every 500 alleles tested) and 0.5% (1 in every 200 alleles tested) seems reasonable to separate rare CYP2D6 alleles or singletons from more common alleles. Tests for an allele in clinical practice should perhaps be based on the ability to detect it at least 3-4 times in one or more population sets of unrelated subjects, before it is considered worthy of testing. If one uses this criteria, the current 58 CYP2D6 alleles may be reduced to only 24 alleles to test in one or more major racial groups: *1, *1xn,*2, *2xn, *3, *4, *4xn, *5, *6, *9, *10, *8/*14, *17, *21, *29, *35, *35xn,*36, *40, *41, *42, *43, *45 and *46. These alleles can be grouped based on functional activity: those with normal CYP2D6 function (*1, *2A, *35, *41(?)), those with no CYP2D6 function (*3, *4, *4xn, *5, *6, *8/*14), those with known or anticipated reduced CYP2D6 function (*9, *10, *17, *29, *36, *40, *41(?), *43, *45, *46) and those alleles that result in overexpression of CYP2D6 activity (*1xn, *2Axn, *35xn). The challenge then lies in refining and elucidating the mechanisms(s) for reduced CYP2D6 enzyme activity in the subset of CYP2D6 alleles with reported diminished activity (*9, *10, *17, *29, *36, *40, *41, *43, *45, *46). Is the reduced activity substratedependent or is the reduced activity globally depressed with regard to all CYP2D6 substrates? Answers to these questions will provide insight into the clinical utility of CYP2D6 genotyping with regard to predicting the therapeutic relevance of the genetic variation. Any novel CYP2D6 alleles identified with some frequency and assigned to the reduced or null CYP2D6 activity group would warrant further investigation.
The difficulty of assessing all of the CYP2D6 alleles or even a reduced number of CYP2D6 alleles by standard PCR methods is a Herculean task. The AmpliChip CYP450 microarray test permits massive parallel testing of various single nucleotides and other more complex polymorphisms in the CYP2D6 gene. This is an excellent tool for predicting CYP2D6 phenotype based on known functional relevance of each CYP2D6 allele. A complete CYP2D6 genotype can be completed in 8 h with an AmpliChip CYP450 microarray system. Standard PCR methods require about 5 days for 19 CYP2D6 separate allele tests (up to $600/CYP2D6 genotype) if carried out on a single isolated sample.
Comprehensive allele analysis by the new AmpliChip CYP450 microarray test, coupled with detection of gene duplications, allows determination of which CYP2D6 allele is duplicated and if it is functional or not. As only three CYP2D6 alleles are believed to produce higher levels of CYP2D6 expression when present at three or more copies (*1, *2, *35), this information may be especially valuable to help guide therapeutic dosing in African-Americans, where Figure 1 The ratio of risperidone/9-OH risperidone in three different groups of African-American patients stabilized on a fixed dose of risperidone/day. The average ratio was obtained from three AfricanAmerican subjects who expressed only the CYP2D6*17 allele, from 10 African-Americans expressing only the *1 or *2A allele, and from three African-Americans expressing only the *10 or *41 CYP2D6 alleles. The typical ratio for CYP2D6 poor metabolizers is 41.0, whereas ultrarapid metabolizers have ratios p0.10.
CYP2D6 Genotype
individuals expressing a higher CYP2D6 activity appear to be more common than previously thought. This new information-rich technology may represent one of the more efficient and reliable solutions to defining the CYP2D6 genotype, where multiple SNPs and differences in the type of SNPs complicate genetic testing in diverse populations from diverse geographical origins.
Materials and methods

Patient recruitment
Before the execution of this research, the study protocol, recruitment and consent were approved by the University of Kentucky IRB committee. Approval to recruit psychiatric patients was given by both the University of Kentucky IRB and the Bluegrass Regional Mental Health-Mental Retardation Board Inc., IRB before their inclusion. One hundred thirty-one African-American subjects (male and female subjects; ages 18-59 years old) were actively recruited from the general population in and around Lexington, Kentucky for assessment of CYP2D6 genotype. Recruitment was based on self-characterization that a subject was African-American and had no current medical problems. Subjects were informed about the purpose of the study, and each subject provided a written informed consent before their participation. A single 10 ml blood sample was collected from each healthy control subject and frozen until processed and tested for various CYP2D6 alleles. An additional 91 AfricanAmerican psychiatric patients (male and female patients; ages 18-73 years old) were recruited from hospitals and outpatient psychiatric clinics in and around central Kentucky. Subject recruitment was voluntary, and subjects signed an informed consent before their participation in this research. For all psychiatric inpatients, a health-care professional confirmed that each patient was able to provide an informed consent before the use of the patient blood sample. A single 10 ml blood sample was collected from each psychiatric subject. The blood was frozen until processed and tested for various CYP2D6 alleles. Psychiatric patients were recruited as part of a larger investigation into the effect of CYP2D6 genetic variation on risperidone adverse effects and discontinuation in the psychiatric patient population. 37, 41 In psychiatric patients stabilized on a fixed risperidone dose, a blood sample was collected at steady state and the levels of 9-hydroxy risperidone and risperidone in plasma were evaluated using a liquid chromatography method as described in a prior publication. 37 Genetic tests DNA was extracted from frozen whole blood as previously described by our lab. 20 Each DNA sample was tested for the CYP2D6*2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *14, *15, *17, *18, *19, *20, *25, *26, *29, *30, *31, *35, *36, *40, *41 alleles and multiple copy *1xn,*2xn,*4xn, *10xn, *17xn, *35xn and *41xn alleles by the new AmpliChip CYP450 prototype microarray assay. All samples were independently tested for the CYP2D6*3, *4, *5, *6, *7, *9, *10, *17, *30, *35, *40, *41, *43, *1xn, *2xn, *4xn, *41xn and *2Lxn alleles by AS-PCR, sequencing or PCR restriction fragment length polymorphism methods as previously described to further assess the new microarray technology performance and reliability. 30 All long PCR methods employed DNA polymerase rTth (XL). Short amplicons (less than 1 kb) were generated with AmpliTaq DNA polymerase. Thermocyclers (9600 and 2400) and DNA polymerases were purchased from Applied Biosystems Inc. (Foster City, CA, USA). Restriction enzymes were purchased from New England Biolabs (Beverly, MA, USA). All primers employed in this research were obtained from Qiagen (Valencia, CA, USA), which purified each primer by HPLC before shipping them. Samples harboring the *40, *30 and*43 alleles as well as the new *58 allele were sequenced over the relevant regions of the CYP2D6 gene to definitively confirm these allele designations (*43 GenBank accession #DQ282154; *58 GenBank accession #DQ282162). For this sequencing, the relevant region of the CYP2D6 gene (intron #1-intron #6, *40, *30 and *58) was amplified by first preparing a 6 kb amplicon of the CYP2D6 gene (À1606-123 bp past end of CYP2D6 gene), and then sub-amplifying a portion of the 6 kb amplicon (a 2.9 kb amplicon) from intron #1 (gene conversion element) into intron #6. As a *43 allele was identified in a *5 genetic background, a 6 kb amplicon containing the entire CYP2D6*43 allele was amplified and sequenced. All amplicons produced for sequencing were purified with the Qiagen MinElute PCR Purification kit (Qiagen Inc., Valencia, CA, USA) and sequenced by the dideoxy termination method at Lark Technologies (Houston, TX, USA).
Statistical analysis
Results are presented as mean values with 95% CI for each allele test. The 95%CI were determined for each allele frequency based on the equation 95% CI ¼ p AE 1:96 Ã ðp Ã ð1 À pÞ=nÞ 1 2 where p is the frequency of allele in the population and n the number of alleles tested.
Hardy-Weinberg equilibrium was analyzed using a w 2 goodness-of-fit test for the major CYP2D6 genotypes. This analysis was carried out on both independent and combined data sets.
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